Historical Valuation
Liminatus Pharma Inc (LIMN) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 0.00. The fair price of Liminatus Pharma Inc (LIMN) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：0.77
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Liminatus Pharma Inc (LIMN) has a current Price-to-Book (P/B) ratio of -10.54. Compared to its 3-year average P/B ratio of -73562.38 , the current P/B ratio is approximately -99.99% higher. Relative to its 5-year average P/B ratio of -73562.38, the current P/B ratio is about -99.99% higher. Liminatus Pharma Inc (LIMN) has a Forward Free Cash Flow (FCF) yield of approximately -56.11%. Compared to its 3-year average FCF yield of -16.51%, the current FCF yield is approximately 239.87% lower. Relative to its 5-year average FCF yield of -16.51% , the current FCF yield is about 239.87% lower.
Competitors Valuation Multiple
AI Analysis
The average P/S ratio for LIMN competitors is 0.35, providing a benchmark for relative valuation. Liminatus Pharma Inc Corp (LIMN.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis
1Y
3Y
5Y
Market capitalization of LIMN increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of LIMN in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is LIMN currently overvalued or undervalued?
Liminatus Pharma Inc (LIMN) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 0.00. The fair price of Liminatus Pharma Inc (LIMN) is between to according to relative valuation methord.
What is Liminatus Pharma Inc (LIMN) fair value?
LIMN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Liminatus Pharma Inc (LIMN) is between to according to relative valuation methord.
How does LIMN's valuation metrics compare to the industry average?
The average P/S ratio for LIMN's competitors is 0.35, providing a benchmark for relative valuation. Liminatus Pharma Inc Corp (LIMN) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Liminatus Pharma Inc (LIMN) as of Jan 17 2026?
As of Jan 17 2026, Liminatus Pharma Inc (LIMN) has a P/B ratio of -10.54. This indicates that the market values LIMN at -10.54 times its book value.
What is the current FCF Yield for Liminatus Pharma Inc (LIMN) as of Jan 17 2026?
As of Jan 17 2026, Liminatus Pharma Inc (LIMN) has a FCF Yield of -56.11%. This means that for every dollar of Liminatus Pharma Inc’s market capitalization, the company generates -56.11 cents in free cash flow.
What is the current Forward P/E ratio for Liminatus Pharma Inc (LIMN) as of Jan 17 2026?
As of Jan 17 2026, Liminatus Pharma Inc (LIMN) has a Forward P/E ratio of 0.00. This means the market is willing to pay $0.00 for every dollar of Liminatus Pharma Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Liminatus Pharma Inc (LIMN) as of Jan 17 2026?
As of Jan 17 2026, Liminatus Pharma Inc (LIMN) has a Forward P/S ratio of 0.00. This means the market is valuing LIMN at $0.00 for every dollar of expected revenue over the next 12 months.